Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2009

View Archived Issues

Snapshots: ICAAC presentations on Novexel's novel beta-lactamase inhibitor NXL-104

NovaBiotics details activity and toxicology studies of onychomycosis treatment NP-213

Pharmacokinetics, tolerability of novel bevirimat tablet formulation assessed in HIV patients

IMC-1121B is well tolerated as second-line treatment in metastatic RCC

MHRA approves continued development of MediGene's RhuDex for rheumatoid arthritis

Zebinix launched in Germany and Austria

Merck & Co presents data on telcagepant evaluation in migraine

MVA-5T4 fails to meet primary endpoint in TRIST survival trial

GSK and XenoPort report phase II results for GSK-1838262 in postherpetic neuralgia

Santhera acquires Oy Juvantia and receives final upfront payment from Biovail

FDA panel supports approval of GSK's Votrient for advanced renal cell carcinoma

GlaxoSmithKline files sNDA with FDA for Avodart in prostate cancer

Biotron completes phase Ib/IIa study of BIT-225 in hepatitis C

Peregrine reports results from phase II bavituximab trial in lung cancer

Physiology or Medicine 2009 Nobel Prize awarded to U.S. scientists for work on telomeres

Novartis and Xenon Pharmaceuticals claim SCD inhibitors for the treatment of dyslipidemia

Tritium-labeled sigma-2 receptor agonists presented by Italian scientists for cancer diagnosis

Chugai Pharmaceutical describes novel PI3Kalpha inhibitors as oncolytics

Onglyza receives marketing authorization in Europe for type 2 diabetes

R-Tech Ueno begins early phase II trial of RK-023 for male pattern baldness

Vantia Therapeutics' VA-111913 enters phase II proof-of-concept trial for dysmenorrhea

Vernalis commences pilot study of V-3381 in patients with chronic cough

Pharmasset to advance PSI-879 into preclinical development for hepatitis C

ThromboGenics reports results of microplasmin trial in diabetic macular edema

Topica reports phase II results for luliconazole for athlete's foot

Transdel presents phase III results for lead topical pain drug, Ketotransdel